American Society of Addiciton Medicine
Aug 9, 2021 Reporting from Rockville, MD
Endorsed Public Policy Statement on Buprenorphine Administration in the Emergency Department
https://www.asam.org/advocacy/public-policy-statements/details/public-policy-statements/2021/08/09/endorsed-public-policy-statement-on-buprenorphine-administration-in-the-emergency-department
Aug 9, 2021
The policy statement acknowledges the increasing number of opioid-related emergency department (ED) visits and fatalities occurring across the nation, before endorsing the administration of buprenorphine to appropriate patients in the ED to treat opioid withdrawal and to reduce the risk of opioid overdose and death following discharge, as well as the administration of buprenorphine in the ED as a bridge to long-term addiction treatment.

Endorsed Public Policy Statement on Buprenorphine Administration in the Emergency Department.Substring(0, maxlength)

American Society of Addictin Medicine

Public Policy Statements

Endorsed Public Policy Statement on Buprenorphine Administration in the Emergency Department

PDF

 

On July 17, 2019, ASAM’s Board of Directors approved ASAM’s endorsement of the American College of Medical Toxicology's position statement "Buprenorphine Administration in the Emergency Department." The policy statement acknowledges the increasing number of opioid-related emergency department (ED) visits and fatalities occurring across the nation, before endorsing the administration of buprenorphine to appropriate patients in the ED to treat opioid withdrawal and to reduce the risk of opioid overdose and death following discharge, as well as the administration of buprenorphine in the ED as a bridge to long-term addiction treatment.